Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A B-cell developmental gene regulatory network is activated in infant AML.
Bolouri H, Ries R, Pardo L, Hylkema T, Zhou W, Smith JL, Leonti A, Loken M, Farrar JE, Triche TJ Jr, Meshinchi S. Bolouri H, et al. Among authors: loken m. PLoS One. 2021 Nov 18;16(11):e0259197. doi: 10.1371/journal.pone.0259197. eCollection 2021. PLoS One. 2021. PMID: 34793513 Free PMC article.
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.
Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ Jr, Nguyen C, Meerzaman D, Loken MR, Oehler VG, Bolouri H, Meshinchi S. Smith JL, et al. Clin Cancer Res. 2020 Feb 1;26(3):726-737. doi: 10.1158/1078-0432.CCR-19-1800. Epub 2019 Nov 12. Clin Cancer Res. 2020. PMID: 31719049 Free PMC article.
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Tarlock K, et al. Among authors: loken mr. Blood. 2021 Sep 30;138(13):1137-1147. doi: 10.1182/blood.2020009652. Blood. 2021. PMID: 33951732 Free PMC article. Clinical Trial.
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S. Ramamurthy R, et al. Among authors: loken mr. Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11. Pediatr Blood Cancer. 2016. PMID: 27511899 Free PMC article.
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.
Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA, Gerbing RB, Correnti C, Loken MR, Broderson LE, Pardo L, Le QH, Tang T, Leonti AR, Smith JL, Chou CK, Xu M, Triche T, Kornblau SM, Kolb EA, Tarlock K, Meshinchi S. Kaeding AJ, et al. Among authors: loken mr. Blood Adv. 2021 May 11;5(9):2350-2361. doi: 10.1182/bloodadvances.2021004424. Blood Adv. 2021. PMID: 33938941 Free PMC article.
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S. Le Q, et al. Among authors: loken mr. Clin Cancer Res. 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11. Clin Cancer Res. 2021. PMID: 34380639 Free PMC article.
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.
Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, Loken MR, Brodersen L, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. Le Q, et al. Among authors: loken mr. J Clin Invest. 2022 Nov 15;132(22):e157101. doi: 10.1172/JCI157101. J Clin Invest. 2022. PMID: 36136600 Free PMC article.
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.
Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, Loken MR, Pardo L, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA. Tarlock K, et al. Clin Cancer Res. 2019 Aug 15;25(16):5038-5048. doi: 10.1158/1078-0432.CCR-18-1897. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182436 Free PMC article.
387 results